Novo Nordisk builds in haemophilia with Bluebird Bio gene editing dealAnxious not to be left behind in the haemophilia market, Novo Nordisk has forged an alliance with Bluebird Share XNovo Nordisk builds in haemophilia with Bluebird Bio gene editing dealhttps://pharmaphorum.com/news/novo-nordisk-builds-in-haemophilia-with-bluebird-bio-gene-editing-deal/
Sobi stays on its acquisitive streak with $915m Dova dealSweden’s Sobi has added another already-marketed product to its rare disease portfolio via a $29 per share takeover Share XSobi stays on its acquisitive streak with $915m Dova dealhttps://pharmaphorum.com/news/sobi-stays-on-its-acquisitive-streak-with-915m-dova-deal/
J&J gets okay for a third first-line Darzalex combo in USJohnson & Johnson continues to extend the use of its Darzalex therapy in newly-diagnosed multiple myeloma patients, getting Share XJ&J gets okay for a third first-line Darzalex combo in UShttps://pharmaphorum.com/news/jj-gets-okay-for-a-third-first-line-darzalex-combo-in-us/
GSK hires former Genentech expert for AI unitGlaxoSmithKline has hired computational drug design specialist Dr Kim Branson to expand its artificial intelligence and machine learning Share XGSK hires former Genentech expert for AI unithttps://pharmaphorum.com/news/gsk-hires-former-genentech-expert-for-ai-unit/
Catalyst’s rival to NovoSeven hits the mark in phase 2 haemophilia trialCatalyst Biosciences is a step closer to challenging Novo Nordisk’s NovoSeven in the haemophilia A and B market Share XCatalyst’s rival to NovoSeven hits the mark in phase 2 haemophilia trialhttps://pharmaphorum.com/news/catalysts-rival-to-novoseven-hits-the-mark-in-phase-2-haemophilia-trial/
FDA clears Karyopharm’s myeloma drug despite advisory panel rejectionThe FDA has taken the unusual step of over-ruling its own advisory committee and approving Karyopharm’s Xpovio as Share XFDA clears Karyopharm’s myeloma drug despite advisory panel rejectionhttps://pharmaphorum.com/news/fda-clears-karyopharms-myeloma-drug-despite-advisory-panel-rejection/
Sobi cuts staff and buys Novimmune drug in refocusSobi has narrowed its focus to haematology and immunology, shedding staff and R&D projects in other areas whilst Share XSobi cuts staff and buys Novimmune drug in refocushttps://pharmaphorum.com/news/sobi-cuts-staff-novimmune-drug-refocus/
Janssen announces first data centres for haematology networkJanssen has announced the first two data centres to join its HONEUR (Haematology Outcomes Network in Europe) collaborative Share XJanssen announces first data centres for haematology networkhttps://pharmaphorum.com/news/janssen-announces-first-data-centres-for-haematology-network/
Novo Nordisk and Celgene lead January pharma M&ANovo’s bid Share XNovo Nordisk and Celgene lead January pharma M&Ahttps://pharmaphorum.com/news/novo-nordisk-celgene-lead-january-pharma-ma/
